^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ER (Estrogen receptor)

    i
    Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
    2d
    Emulation of the PALOMA-2 Trial (clinicaltrials.gov)
    P=N/A, N=6097, Active, not recruiting, Brigham and Women's Hospital | Trial completion date: Oct 2025 --> Mar 2026 | Trial primary completion date: Oct 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • letrozole
    2d
    X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov)
    P1, N=52, Recruiting, Immunolight, LLC | N=20 --> 52
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • ER negative
    |
    methoxsalen (X-PACT)
    2d
    IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=540, Not yet recruiting, Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
    New P3 trial
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive
    |
    Herceptin (trastuzumab) • paclitaxel • docetaxel • Perjeta (pertuzumab) • IBI-354
    2d
    FACT-TN: FMD and Neoadjuvant Chemo-immunotherapy in TNBC (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    docetaxel • Loqtorzi (toripalimab-tpzi) • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    2d
    Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer (clinicaltrials.gov)
    P3, N=160, Active, not recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    MammaPrint®
    |
    paclitaxel • doxorubicin hydrochloride • Irene (pyrotinib) • cyclophosphamide • epirubicin
    2d
    Evaluating the prognostic significance of HIST1H4C in breast cancer: implications for neoadjuvant therapy. (PubMed, Sci Rep)
    Furthermore, high HIST1H4C expression before and after-treatment in our center or in database has a positively correlation with poor prognosis. HIST1H4C is the potential biomarker of neoadjuvant therapy and prognosis for breast cancer.
    Journal
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER negative
    2d
    Evaluation of the new European risk classification for endometrial carcinoma: a cohort study. (PubMed, Int J Gynecol Cancer)
    The ESGO-ESTRO-ESP 2025 classification re-assigns approximately one-tenth of patients, with a meaningful impact on adjuvant therapy. The rarity of estrogen receptor negativity limits its role in no-specific-molecular-profile stratification. Variation in lymph node involvement across molecular tumor categories highlights opportunities for individualized surgical staging.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive • MSI-H/dMMR • ER negative
    2d
    CDK4/6 Inhibitors in HER2-positive Metastatic Breast Cancer. (PubMed, Clin Breast Cancer)
    The integration of CDK4/6 inhibitors into anti-HER2 treatment strategies represents a promising approach to address the unique biology of HR + /HER2 + BC. Molecular profiling and personalized treatment strategies are essential to optimize patient outcomes and reduce unnecessary toxicity.
    Review • Journal
    |
    ER (Estrogen receptor)
    |
    HER-2 positive
    3d
    Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective study. (PubMed, Int J Clin Oncol)
    An ALC ≥ 1000/μL at ERI completion was associated with an improved post-ERI OS (OS2). It is suggested that not only the factors at the initiation of ERI, but also the immunological status at the end of ERI, may have prognostic value after ERI.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Halaven (eribulin mesylate)
    3d
    Longitudinal Changes in the Vaginal Microbiome During Endocrine Therapy in Premenopausal Breast Cancer and Their Association with Genitourinary Syndrome of Menopause (GSM): A Single-Center Prospective Cohort Study. (ChiCTR2500115283)
    P=N/A, N=110, Not yet recruiting, Women's Hospital School of Medicine Zhejiang University; Women's Hospital School of Medicine Zhejiang University
    New trial
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PGR positive
    3d
    ‌A Phase II, Two-Stage Study Evaluating the Efficacy of Entinostat in Combined with Fulvestrant in Locally Advanced or Metastatic Breast Cancer with Recurrence or Progression after CDK4/6 Inhibitor plus Endocrine Therapy (ChiCTR2500114131)
    P=N/A, N=50, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative
    |
    fulvestrant • Jingzhuda (entinostat)